Publication

Article

Pharmacy Times

Volume00

pharmacy Pet Peeves

Articles in this issue
advertiserINDEX
productHOTLINE
Motion Sickness: Calming the Waves of Upset
pharmacy Pet Peeves
recruitment/RESOURCES
canyouREADtheseRxs?

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!
Related Videos
Practice Pearl #1 Active Surveillance vs Treatment in Patients with NETs
Related Content
Navigating Biosimilars and 505(b)(2) Drugs in Oncology: Operational, Clinical, and Policy Strategies for Pharmacists
August 15th 2025

Navigating Biosimilars and 505(b)(2) Drugs in Oncology: Operational, Clinical, and Policy Strategies for Pharmacists

Alana Hippensteele, Lead Editor
White pills with a red exclamation mark symbolize medication safety alert - Image credit: TensorSpark | stock.adobe.com
August 15th 2025

Promote Patient Safety With a Just Culture

Kathleen Kenny, PharmD
According to this online tool, this medication will work best. Shot of a pharmacist using her digital tablet while working in a isle. | Image Credit: Nikish Hiraman/peopleimages.com | stock.adobe.com
August 15th 2025

Leveraging Pharmacy Expertise and Data Systems to Meet EOM Benchmarks

Alana Hippensteele, Lead Editor
Prague,Czech republic-June 17 2024: Jardiance box of medication with Empagliflozin active substance by Boehringer Ingelheim,used for treatment of Type 2 diabetes,Heart failure,Hyperglycemia - Image credit: Semi | stock.adobe.com
August 15th 2025

A Few Key Points Can Guide SGLT2 Inhibitor Management

Jeannette Y. Wick, MBA, RPh, FASCP
Toothbrush, toothpaste and woman brushing teeth in bathroom for health, happiness and wellness in morning. Girl, cleaning mouth for dental care and oral hygiene or smile in home with mockup space - Image credit: Jadon B/peopleimages.com | stock.adobe.com
August 15th 2025

OTC Case Studies: Oral Care

Sneha Baxi Srivastava, PharmD, BCACP, CDE Rupal Patel Mansukhani, PharmD, FAPhA, NCTTP
From ECHELON-3 to Clinical Practice: Newly Approved Brentuximab Vedotin With Lenalidomide and Rituximab for R/R DLBCL
August 15th 2025

From ECHELON-3 to Clinical Practice: Newly Approved Brentuximab Vedotin With Lenalidomide and Rituximab for R/R DLBCL

Ami Ali, PharmD, BCOP Melissa Martinez, PharmD Martina Nasralla, PharmD Candidate Zyanya Rizzo, PharmD Candidate Lamya Al-Saleh, PharmD, RPh